SEARCH

SEARCH BY CITATION

References

  • 1
    Bosch J & Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32(Suppl. 1): 14156.
  • 2
    Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 1981; 80: 51825.
  • 3
    Kravetz D, Bosch J, Arderiu MT, et al. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 1988; 254: G3228.
  • 4
    Cirera I, Feu F, Luca A, et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology 1995; 22: 10611.
  • 5
    Eriksson LS, Brundin T, Soderlund C, Wahren J. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987; 22: 91925.
  • 6
    McKee R. A study of octreotide in oesophageal varices. Digestion 1990; 45(Suppl. 1): 604, Discussion 65.
  • 7
    Lin HC, Tsai YT, Lee FY, et al. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology 1992; 103: 22934.
  • 8
    Chatila R, Ferayorni L, Gupta T, Groszmann RJ. Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. Hepatology 2000; 31: 5726.
  • 9
    Sabat M, Guarner C, Soriano G, et al. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites. Dig Dis Sci 1998; 43: 21849.
  • 10
    Huang YT, Tsai JF, Liu TB, Hong CY, Yang MC, Lin HC. Chronic administration of octreotide increases vascular responsiveness in rats with portal hypertension. Clin Sci 1996; 91: 6016.
  • 11
    Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999; 276: G104351.
  • 12
    Szentivanyi M Jr, Nadasy GL, Dezsi L, Mozes G, Tulassay T, Monos E. Nitric oxide-dependent opposite effects of somatostatin on arterial and venous caliber in situ. Am J Physiol 1996; 271: H223845.
  • 13
    Sieber CC, Lee FY, Groszmann RJ. Long-term octreotide treatment prevents vascular hyporeactivity in portal-hypertensive rats. Hepatology 1996; 23: 121823.
  • 14
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 6469.
  • 15
    Notas G, Xidakis C, Valatas V, Kouroumalis A, Kouroumalis EA. Levels of circulating endothelin-1 and nitrates/nitrites in patients with virus-related hepatocellular carcinoma. J Viral Hepatitis, 2001; 8: 639.
  • 16
    Kouroumalis EA, Koutroubakis IE, Manousos ON. Somatostatin for acute severe bleeding from portal hypertensive gastropathy. Eur J Gastroenterol Hepatol 1998; 10: 50912.
  • 17
    Tyden G, Samnegard H, Thulin L, Muhrbeck O, Efendic S. Circulatory effects of somatostatin in anesthetized man. Acta Chir Scand 1979; 145: 4436.
  • 18
    Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997; 350: 14959.DOI: 10.1016/s0140-6736(97)05099-x
  • 19
    Cerini R, Lee SS, Hadengue A, Koshy A, Girod C, Lebrec D. Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. Gastroenterology 1988; 94: 7038.
  • 20
    Nevens F, Steenbergen W, Yap SH, Fevery J. Assessment of variceal pressure by continuous non-invasive endoscopic registration: a placebo controlled evaluation of the effect of terlipressin and octreotide. Gut 1996; 38: 12934.
  • 21
    Moller S, Brinch K, Henriksen JH, Becker U. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 1997; 26: 102633.
  • 22
    Burroughs AK & Patch D. Therapeutic benefit of vaso-active drugs for acute variceal bleeding: a real pharmacological effect, or a side-effect of definitions in trials? Hepatology 1996; 24: 7379.
  • 23
    Pringle SD, McKee RF, Garden OJ, Lorimer AR, Carter DC. The effect of a long-acting somatostatin analogue on portal and systemic haemodynamics in cirrhosis. Aliment Pharmacol Ther 1988; 2: 4519.
  • 24
    McCormick PA, Seifalian AM, Stansby G, et al. Superior mesenteric artery blood flow in man measured with intra-arterial Doppler catheters: effect of octreotide. J Hepatol 1993; 17: 207.
  • 25
    Vallance P & Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 7768.
  • 26
    Pizcueta P, Pique JM, Fernandez M, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 190915.
  • 27
    Pizcueta MP, Pique JM, Bosch J, Whittle BJ, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992; 105: 18490.
  • 28
    Arias-Diaz J, Vara E, Torres-Melero J, Garcia C, Hernandez J, Balibrea JL. Local production of oxygen free radicals and nitric oxide in rat diaphragm during sepsis: effects of pentoxifylline and somatostatin. Eur J Surg 1997; 163: 61925.
  • 29
    Chao TC, Cheng HP, Walter RJ. Somatostatin and macrophage function: modulation of hydrogen peroxide, nitric oxide and tumor necrosis factor release. Regul Pept 1995; 58: 110.DOI: 10.1016/0167-0115(95)00051-c
  • 30
    Dezsi L, Szentivanyi M Jr, Dornyei G, et al. Regional differences in nitric oxide-dependent vascular responses to somatostatin. Physiol Res 1996; 45: 2916.